Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer.

Authors

Xuanfeng Ding, Beaumont Health
Xiaoqiang Li, Beaumont Health
An Qin, Beaumont Health
Jun Zhou, Beaumont Health
Di Yan, Beaumont Health
Craig Stevens, Beaumont Health
Daniel Krauss, Beaumont Health
Peyman Kabolizdeh, Beaumont Health

Document Type

Article

Publication Date

3-1-2018

Publication Title

Acta oncologica (Stockholm, Sweden)

Volume

57

Issue

3

First Page

435

Last Page

437

Recommended Citation

Ding X, Li X, Qin A, Zhou J, Yan D, Stevens C, Krauss D, Kabolizdeh P. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018 Mar;57(3):435-437. doi: 10.1080/0284186X.2017.1358463. Epub 2017 Aug 3. PMID: 28774218.

DOI

10.1080/0284186X.2017.1358463

ISSN

1651-226X

PubMed ID

28774218